Quarterly report pursuant to Section 13 or 15(d)

Accrued expenses and other current liabilities

v3.7.0.1
Accrued expenses and other current liabilities
 3 Months Ended
Mar. 31, 2017
Accrued expenses and other current liabilities  
Accrued expenses and other current liabilities

Note 7 — Accrued expenses and other current liabilities

 

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

 

March 31,
2017

 

December 31,
2016

 

 

 

 

 

 

 

Accrued clinical and development expenses

 

$
5,373

 

$
4,938

 

Accrued employee compensation and benefits payable

 
2,767

 
4,539

 

Accrued capital expenditure

 
4,190

 
3,954

 

Value added tax (VAT)

 

—

 
2,014

 

Other accrued purchases

 
1,498

 
1,003

 

Other current liabilities

 
1,282

 
1,080

 

 

 

 

 

 

 

 

 

$
15,110

 

$
17,528

 

 

 

 

 

 

 

 

 

 

The Company typically has a receivable for VAT.  At December 31, 2016 there was a VAT payable due to VAT arising on the milestone payments invoiced to GSK in 2016.  There were no milestone payments invoiced to GSK in the three months ended March 31, 2017 and therefore no VAT payable at March 31, 2017.